A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Injection in Patients With Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-type

Trial Profile

A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Injection in Patients With Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-type

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs MRG 106 (Primary) ; MRG 106 (Primary) ; MRG 106 (Primary)
  • Indications Cutaneous T cell lymphoma; Mycosis fungoides
  • Focus Adverse reactions; First in man
  • Sponsors miRagen Therapeutics
  • Most Recent Events

    • 11 Aug 2017 According to a miRagen Therapeutics media release, interim data will be presented at ASH in Q4 2017.
    • 11 Aug 2017 New interim results published in a miRagen Therapeutics media release.
    • 11 Aug 2017 According to a miRagen Therapeutics media release, Following a discussion with the FDA in June, the Company plans to evaluate MRG-106 in additional oncology indications within the current Phase 1 trial, including adult T-cell leukemia/lymphoma (ATLL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL) as in each case the disease process appears to be related to an increase in miR-155 levels.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top